Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.The diagnostic evaluation of patients with this syndrome is complicated. Then hold white collar on syringe and carefully pull the transparent needle protector straight off.Hold needle upright and tap gently to make any air bubbles rise to the top. The recommended dose for the treatment of schizophrenia is 25 mg IM every 2 weeks.

The above effects showed little or no reversibility in females after a 12 week drug-free recovery period.In a study in which juvenile rats were treated with oral risperidone from days 12 to 50 of age, a reversible impairment of performance in a test of learning and memory was seen, in females only, with a no-effect dose of 0.63 mg/kg/day.

Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of Risperdal ConstaPatients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. RISPERDAL CONSTA ® (risperidone) long-acting injection is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder and for the treatment of schizophrenia. RISPERDAL® CONSTA® requires close attention to these step-by-step Instructions for Use to help ensure successful administration. Risperdal ConstaA potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc.WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis Therefore, appropriate supportive measures should be instituted. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Adverse reactions are adverse events that were considered to be reasonably associated with the use of Risperdal ConstaThe majority of all adverse reactions were mild to moderate in severity.Table 4 lists the adverse reactions reported in 2% or more of Risperdal ConstaTable 5 lists the treatment-emergent adverse reactions reported in 2% or more of Risperdal ConstaTable 6 lists the treatment-emergent adverse reactions reported in 4% or more of patients in the 52-week double-blind, placebo-controlled treatment phase of a trial assessing the efficacy and safety of Risperdal ConstaThe following additional adverse reactions occurred in < 2% of the Risperdal ConstaAdditional Adverse Reactions Reported with Oral RISPERDALThe following is a list of additional adverse reactions that have been reported during the clinical trial evaluation of oral RISPERDALIn the 24-month double-blind, placebo-controlled treatment period of the trial assessing the efficacy and safety of Risperdal ConstaIn the 52-week double-blind phase of the placebo-controlled trial in which Risperdal ConstaTwo methods were used to measure extrapyramidal symptoms (EPS) in the 12-week double-blind, placebo-controlled trial comparing three doses of Risperdal ConstaAs shown in Table 1, the overall incidence of EPS-related adverse reactions (akathisia, dystonia, parkinsonism, and tremor) in patients treated with 25 mg Risperdal ConstaThe median change from baseline to endpoint in total ESRS score showed no worsening in patients treated with Risperdal ConstaThe electrocardiograms of 202 schizophrenic patients treated with 25 mg or 50 mg Risperdal ConstaThe electrocardiograms of 227 patients with Bipolar I Disorder were evaluated in the 24-month double-blind, placebo-controlled period. Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of risperidone-induced alpha blockade). However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. In plasma, risperidone is bound to albumin and α1-acid glycoprotein.

Push vial adapter straight down onto vial top until it snaps securely into place.Keep vial vertical to prevent leakage. Close medical supervision and monitoring should continue until the patient recovers.Risperidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives.

This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.

In one peri/post-natal development study, there was an increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the oral MRHD on a mg/mPlacental transfer of risperidone occurs in rat pups. The clinical effects of this dose adjustment should not be anticipated earlier than 3 weeks after the first injection with the higher dose.In patients with clinical factors such as hepatic or renal impairment or certain drug interactions that increase risperidone plasma concentrations Do not combine two different dose strengths of Risperdal ConstaPatients with renal or hepatic impairment should be treated with titrated doses of oral RISPERDALPatients with renal impairment may have less ability to eliminate risperidone than normal adults. The possibility of multiple drug involvement should be considered. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites.